EPI-Net One Health reporting guideline for antimicrobial consumption and resistance surveillance data : a Delphi approach
© 2022 The Authors..
Strategic and standardised approaches to analysis and reporting of surveillance data are essential to inform antimicrobial resistance (AMR) mitigation measures, including antibiotic policies. Targeted guidance on linking full-scale AMR and antimicrobial consumption (AMC)/antimicrobial residues (AR) surveillance data from the human, animal, and environmental sectors is currently needed. This paper describes the initiative whereby a multidisciplinary panel of experts (56 from 20 countries-52 high income, 4 upper middle or lower income), representing all three sectors, elaborated proposals for structuring and reporting full-scale AMR and AMC/AR surveillance data across the three sectors. An evidence-supported, modified Delphi approach was adopted to reach consensus among the experts for dissemination frequency, language, and overall structure of reporting; core elements and metrics for AMC/AR data; core elements and metrics for AMR data. The recommendations can support multisectoral national and regional plans on antimicrobials policy to reduce resistance rates applying a One Health approach.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
The Lancet regional health. Europe - 26(2023) vom: 01. März, Seite 100563 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Babu Rajendran, Nithya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibiotic policy |
|---|
| Anmerkungen: |
Date Revised 11.03.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.lanepe.2022.100563 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354011391 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354011391 | ||
| 003 | DE-627 | ||
| 005 | 20231226061310.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lanepe.2022.100563 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM354011391 | ||
| 035 | |a (NLM)36895445 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Babu Rajendran, Nithya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a EPI-Net One Health reporting guideline for antimicrobial consumption and resistance surveillance data |b a Delphi approach |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.03.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Authors. | ||
| 520 | |a Strategic and standardised approaches to analysis and reporting of surveillance data are essential to inform antimicrobial resistance (AMR) mitigation measures, including antibiotic policies. Targeted guidance on linking full-scale AMR and antimicrobial consumption (AMC)/antimicrobial residues (AR) surveillance data from the human, animal, and environmental sectors is currently needed. This paper describes the initiative whereby a multidisciplinary panel of experts (56 from 20 countries-52 high income, 4 upper middle or lower income), representing all three sectors, elaborated proposals for structuring and reporting full-scale AMR and AMC/AR surveillance data across the three sectors. An evidence-supported, modified Delphi approach was adopted to reach consensus among the experts for dissemination frequency, language, and overall structure of reporting; core elements and metrics for AMC/AR data; core elements and metrics for AMR data. The recommendations can support multisectoral national and regional plans on antimicrobials policy to reduce resistance rates applying a One Health approach | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antibiotic policy | |
| 650 | 4 | |a Antimicrobial consumption | |
| 650 | 4 | |a Antimicrobial resistance | |
| 650 | 4 | |a One Health | |
| 650 | 4 | |a Surveillance | |
| 700 | 1 | |a Arieti, Fabiana |e verfasserin |4 aut | |
| 700 | 1 | |a Mena-Benítez, Carla Alejandra |e verfasserin |4 aut | |
| 700 | 1 | |a Galia, Liliana |e verfasserin |4 aut | |
| 700 | 1 | |a Tebon, Maela |e verfasserin |4 aut | |
| 700 | 1 | |a Alvarez, Julio |e verfasserin |4 aut | |
| 700 | 1 | |a Gladstone, Beryl Primrose |e verfasserin |4 aut | |
| 700 | 1 | |a Collineau, Lucie |e verfasserin |4 aut | |
| 700 | 1 | |a De Angelis, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Duro, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Gaze, William |e verfasserin |4 aut | |
| 700 | 1 | |a Göpel, Siri |e verfasserin |4 aut | |
| 700 | 1 | |a Kanj, Souha S |e verfasserin |4 aut | |
| 700 | 1 | |a Käsbohrer, Annemarie |e verfasserin |4 aut | |
| 700 | 1 | |a Limmathurotsakul, Direk |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez de Abechuco, Estibaliz |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzolini, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Mutters, Nico T |e verfasserin |4 aut | |
| 700 | 1 | |a Pezzani, Maria Diletta |e verfasserin |4 aut | |
| 700 | 1 | |a Presterl, Elisabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Renk, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Baño, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Săndulescu, Oana |e verfasserin |4 aut | |
| 700 | 1 | |a Scali, Federico |e verfasserin |4 aut | |
| 700 | 1 | |a Skov, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Velavan, Thirumalaisamy P |e verfasserin |4 aut | |
| 700 | 1 | |a Vuong, Cuong |e verfasserin |4 aut | |
| 700 | 1 | |a Tacconelli, Evelina |e verfasserin |4 aut | |
| 700 | 0 | |a EPI-Net One Health consensus working group |e verfasserin |4 aut | |
| 700 | 1 | |a Adegnika, Ayola Akim |e investigator |4 oth | |
| 700 | 1 | |a Avery, Lisa |e investigator |4 oth | |
| 700 | 1 | |a Bonten, Marc |e investigator |4 oth | |
| 700 | 1 | |a Cassini, Alessandro |e investigator |4 oth | |
| 700 | 1 | |a Chauvin, Claire |e investigator |4 oth | |
| 700 | 1 | |a Compri, Monica |e investigator |4 oth | |
| 700 | 1 | |a Damborg, Peter |e investigator |4 oth | |
| 700 | 1 | |a De Greeff, Sabine |e investigator |4 oth | |
| 700 | 1 | |a Del Toro, Maria Dolores |e investigator |4 oth | |
| 700 | 1 | |a Filter, Matthias |e investigator |4 oth | |
| 700 | 1 | |a Franklin, Alison |e investigator |4 oth | |
| 700 | 1 | |a Gonzalez-Zorn, Bruno |e investigator |4 oth | |
| 700 | 1 | |a Grave, Kari |e investigator |4 oth | |
| 700 | 1 | |a Hocquet, Didier |e investigator |4 oth | |
| 700 | 1 | |a Hoelzle, Ludwig E |e investigator |4 oth | |
| 700 | 1 | |a Kalanxhi, Erta |e investigator |4 oth | |
| 700 | 1 | |a Laxminarayan, Ramanan |e investigator |4 oth | |
| 700 | 1 | |a Leibovici, Leonard |e investigator |4 oth | |
| 700 | 1 | |a Malhotra-Kumar, Surbhi |e investigator |4 oth | |
| 700 | 1 | |a Mendelson, Marc |e investigator |4 oth | |
| 700 | 1 | |a Paul, Mical |e investigator |4 oth | |
| 700 | 1 | |a Muñoz Madero, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Murri, Rita |e investigator |4 oth | |
| 700 | 1 | |a Piddock, Laura Jv |e investigator |4 oth | |
| 700 | 1 | |a Ruesen, Carolien |e investigator |4 oth | |
| 700 | 1 | |a Sanguinetti, Maurizio |e investigator |4 oth | |
| 700 | 1 | |a Schilling, Thorben |e investigator |4 oth | |
| 700 | 1 | |a Schrijver, Remco |e investigator |4 oth | |
| 700 | 1 | |a Schwaber, Mitchell J |e investigator |4 oth | |
| 700 | 1 | |a Scudeller, Luigia |e investigator |4 oth | |
| 700 | 1 | |a Torumkuney, Didem |e investigator |4 oth | |
| 700 | 1 | |a Van Boeckel, Thomas |e investigator |4 oth | |
| 700 | 1 | |a Vanderhaeghen, Wannes |e investigator |4 oth | |
| 700 | 1 | |a Voss, Andreas |e investigator |4 oth | |
| 700 | 1 | |a Wozniak, Teresa |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet regional health. Europe |d 2021 |g 26(2023) vom: 01. März, Seite 100563 |w (DE-627)NLM323979734 |x 2666-7762 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2023 |g day:01 |g month:03 |g pages:100563 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lanepe.2022.100563 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2023 |b 01 |c 03 |h 100563 | ||